Cardiac Raptor Ablation Impairs Adaptive Hypertrophy, Alters Metabolic Gene Expression, and Causes Heart Failure in Mice
暂无分享,去创建一个
M. Hall | R. Lerch | M. Brink | M. Rüegg | T. Pedrazzini | F. Zorzato | I. Plaisance | C. Berthonneche | J. Krishnan | C. Pellieux | C. Morandi | Pankaj S. Shende | M. Hall
[1] M. Latronico,et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. , 2010, The Journal of clinical investigation.
[2] E. Abel,et al. Mammalian Target of Rapamycin Is a Critical Regulator of Cardiac Hypertrophy in Spontaneously Hypertensive Rats , 2009, Hypertension.
[3] U. Eriksson,et al. Myeloid Differentiation Factor-88/Interleukin-1 Signaling Controls Cardiac Fibrosis and Heart Failure Progression in Inflammatory Dilated Cardiomyopathy , 2009, Circulation research.
[4] Y. Pinto,et al. Avoidance of Transient Cardiomyopathy in Cardiomyocyte-Targeted Tamoxifen-Induced MerCreMer Gene Deletion Models , 2009, Circulation research.
[5] R. Cooksey,et al. Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. , 2009, Cardiovascular research.
[6] P. Polak,et al. mTOR and the control of whole body metabolism. , 2009, Current opinion in cell biology.
[7] J. Blenis,et al. Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy , 2009, Cell cycle.
[8] M. Hall,et al. mTOR-what does it do? , 2008, Transplantation proceedings.
[9] Sang Gyun Kim,et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.
[10] E. Casanova,et al. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. , 2008, Cell metabolism.
[11] J. Auwerx,et al. Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. , 2008, Cell metabolism.
[12] M. Rubart,et al. Cardiac Restricted Overexpression of Kinase-dead Mammalian Target of Rapamycin (mTOR) Mutant Impairs the mTOR-mediated Signaling and Cardiac Function* , 2008, Journal of Biological Chemistry.
[13] V. Mootha,et al. mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.
[14] Mi-Sung Kim,et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. , 2007, The Journal of clinical investigation.
[15] J. P. McCoy,et al. The Mammalian Target of Rapamycin (mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative Capacity* , 2006, Journal of Biological Chemistry.
[16] Corinne Pellieux,et al. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. , 2006, Journal of molecular and cellular cardiology.
[17] A. Dart,et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis , 2006, Journal of hypertension.
[18] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[19] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[20] D. Severson,et al. Increased myocardial oxygen consumption reduces cardiac efficiency in diabetic mice. , 2006, Diabetes.
[21] I. Shiojima,et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.
[22] William C Stanley,et al. Myocardial substrate metabolism in the normal and failing heart. , 2005, Physiological reviews.
[23] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[24] D. Severson,et al. Effect of BM 17.0744, a PPARalpha ligand, on the metabolism of perfused hearts from control and diabetic mice. , 2005, Canadian journal of physiology and pharmacology.
[25] J. Robbins,et al. Impact of beta-myosin heavy chain expression on cardiac function during stress. , 2004, Journal of the American College of Cardiology.
[26] V. Giguère,et al. Estrogen-Related Receptor α Directs Peroxisome Proliferator-Activated Receptor α Signaling in the Transcriptional Control of Energy Metabolism in Cardiac and Skeletal Muscle , 2004, Molecular and Cellular Biology.
[27] J. Blenis,et al. Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy , 2004, Molecular and Cellular Biology.
[28] M. Boluyt,et al. The mTOR/p70S6K Signal Transduction Pathway Plays a Role in Cardiac Hypertrophy and Influences Expression of Myosin Heavy Chain Genes in vivo , 2004, Cardiovascular Drugs and Therapy.
[29] S. Izumo,et al. Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload , 2004, Circulation.
[30] V. Giguère,et al. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. , 2004, Molecular and cellular biology.
[31] E. Olson,et al. Cardiac hypertrophy: the good, the bad, and the ugly. , 2003, Annual review of physiology.
[32] W. Manning,et al. Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice , 2003, Circulation.
[33] F. Netter,et al. Supplemental References , 2002, We Came Naked and Barefoot.
[34] S. Cook,et al. Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.
[35] D. Severson,et al. A Role for Peroxisome Proliferator-activated Receptor α (PPARα) in the Control of Cardiac Malonyl-CoA Levels , 2002, The Journal of Biological Chemistry.
[36] R. Lerch,et al. Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism. , 2001, Cardiovascular research.
[37] M. Crackower,et al. Temporally Regulated and Tissue-Specific Gene Manipulations in the Adult and Embryonic Heart Using a Tamoxifen-Inducible Cre Protein , 2001, Circulation research.
[38] Tobias Schmelzle,et al. TOR, a Central Controller of Cell Growth , 2000, Cell.
[39] E. Lakatta,et al. Rapamycin inhibits alpha 1-adrenergic receptor-stimulated cardiac myocyte hypertrophy but not activation of hypertrophy-associated genes. Evidence for involvement of p70 S6 kinase. , 1997, Circulation research.
[40] D. Kelly,et al. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. , 1996, Circulation.
[41] A. Gingras,et al. Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.
[42] J. Sadoshima,et al. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. , 1995, Circulation research.
[43] J. Ross,et al. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. , 1994, The American journal of physiology.
[44] H. Taegtmeyer. Energy metabolism of the heart: from basic concepts to clinical applications. , 1994, Current problems in cardiology.
[45] S. Shaughnessy,et al. Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.